Wenrui Wang
Case Report: Regenerative hepatic pseudotumor induced by tislelizumab in a lung cancer patient
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment for different types of cancers, providing significant clinical benefits. However, these therapies are associated with various immune-related adverse events (irAEs), including hepatic…